Poseida Therapeutics
| General Information | |
| Business: |
We are a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. |
| Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
| Employees: | 149 |
| Founded: | 2014 |
| Contact Information | |
| Address | 9390 Towne Centre Drive, Suite 200, San Diego, California 92121, US |
| Phone Number | 858-779-3100 |
| Web Address | http://www.poseida.com |
| View Prospectus: | Poseida Therapeutics |
| Financial Information | |
| Market Cap | $989mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-102.0 mil (last 12 months) |
| IPO Profile | |
| Symbol | PSTX |
| Exchange | NASDAQ |
| Shares (millions): | 14.0 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $224.0 mil |
| Manager / Joint Managers | BofA Securities/ Piper Sandler/ William Blair |
| CO-Managers | - |
| Expected To Trade: | 7/10/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |